HomeFinanceWhat is happening with Can-Fite BioPharma Ltd. (CANF) Stock?

What is happening with Can-Fite BioPharma Ltd. (CANF) Stock?

Maxim Group raised the price target for the Can-Fite BioPharma Ltd. (AMEX:CANF) stock to “a Buy”. The rating was released on August 11, 2017, according to finviz. The research report from Rodman & Renshaw has resumed the stock to Buy, with a price target set at $6. The stock was reiterated by H.C. Wainwright, who disclosed in a research note on November 30, 2015, to Buy and set the price objective to $6. In their research brief published March 31, 2015, H.C. Wainwright analysts reiterated the Can-Fite BioPharma Ltd. stock to Buy with a price target of $3.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Can-Fite BioPharma Ltd. (AMEX:CANF) dipped -6.32% to close Tuesday’s market session at $4.74, lower as compared to yesterday’s close. The stock price fluctuated between $4.44 and $5.36 throughout the trading session with the volume trading being 1337594 shares, which represented a significant variation when compared to the three months average volume of 20.58K shares. The firm’s stock price fluctuated -15.36% within the last five trades and -30.29% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -44.24% in the last 6 months and -36.54% was subtracted to its value over the previous 3 months. CANF stock is trading at a margin of -18.54%, -32.81% and -43.58% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


As of the close of trading, CANF deals in the Healthcare domain. The stock is trading -63.26 percent below its 52-week high and 3.72 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -64.22. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Can-Fite BioPharma Ltd.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $15.99 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 19.57 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.76, which equates the market value of a stock with its book value.



Please enter your comment!
Please enter your name here

Recent Post